Search
2 results for "rare-diseases"
Biohacking
FDA Delays: The Hidden Risk in Your Health Optimization Protocol and H
A 4-month FDA delay forced a biotech company to close, halting research on autoimmune hepatitis and eliminating a promising therapy for rare disease patients. T
STAT News
Biohacking
Regulatory Risk: The Systemic Threat to Health Innovation and Patient
A 4-month FDA delay forced a biotech company to close, exposing systemic vulnerabilities that directly impact patients with rare diseases. This case highlights
STAT News